DURECT (NASDAQ:DRRX) will be issuing its Q3 quarterly earnings data after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter.
Shares of DURECT stock opened at $1.02 on Monday. The company has a quick ratio of 3.36, a current ratio of 3.60 and a debt-to-equity ratio of 0.44. The firm has a market cap of $162.00 million, a price-to-earnings ratio of -34.00 and a beta of 0.91. DURECT has a 12 month low of $0.82 and a 12 month high of $2.55.
Separately, HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of DURECT in a research report on Tuesday, July 31st.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand.
See Also: How Investors Use a Balance Sheet
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.